uniQure to Participate in Multiple Upcoming Industry Conferences in March
February 26, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in February
February 01, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
December 21, 2020 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Dec. 21, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in December
December 02, 2020 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
November 04, 2020 10:46 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in November
November 04, 2020 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
October 27, 2020 07:05 ET
|
uniQure Inc.
~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease ~ ~ Top-Line Data from HOPE-B Pivotal Trial in Hemophilia B Expected Before Year End ~ ...
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
July 30, 2020 07:05 ET
|
uniQure Inc.
~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~ ~ Completed First Patient Dosing in...
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
June 24, 2020 16:05 ET
|
uniQure Inc.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...
uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
June 19, 2020 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...